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Summary 
Objective. — To investigate the cause of transient weakness in myotonia congenita (MC) and the 
mechanism of action of mexiletine in reducing weakness. 
Methods. — The changes in neuromuscular excitability produced by 1 min of maximal voluntary 
contractions (MVC) were measured on the amplitude of compound muscle action potentials 
(CMAP) in two patients with either recessive or dominant MC, compared to control values 
obtained in 20 healthy subjects. Measurements were performed again in MC patients after 
mexiletine therapy. 
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Results. — Transient reduction in maximal CMAP amplitude lasting several minutes after MVC 
was evident in MC patients, whereas no change was observed in controls. Mexiletine efﬁciently 
reduced this transient CMAP depression in both patients. 
Discussion. — Transient CMAP depression following sustained MVC may represent the electro- 
physiological correlate of the weakness clinically experienced by the patients. In MC, the low 
chloride conductance could induce self-sustaining action potentials after MVC, determining 
progressive membrane depolarization and a loss of excitability of muscle ﬁbers, thus result- 
ing in transient paresis. Mexiletine may prevent conduction block due to excessive membrane 
depolarization, thus reducing the transient CMAP depression following sustained MVC. 
 
 
Résumé 
Objectif. — Étudier la cause de la faiblesse transitoire dans la myotonie congénitale (MC) et le 
mécanisme d’action de la mexilétine pour la réduire. 
Méthodes. — Les modiﬁcations d’excitabilité neuromusculaire produites par 1 min de contrac- 
tion volontaire maximale ont été mesurées sur l’amplitude du potentiel global d’action 
musculaire (PGAM) chez deux patients présentant une MC récessive ou dominante, compar- 
ativement aux valeurs témoins obtenues chez 20 sujets sains. Les mesures ont été effectuées 
à nouveau chez les patients MC après traitement par la mexilétine. 
Résultats. — La réduction transitoire de l’amplitude maximale du PGAM était évidente pendant 
plusieurs minutes après contraction volontaire maximale chez les patients MC, alors qu’aucun 
changement n’était observé chez les témoins. La mexilétine a efﬁcacement réduit cette dépres- 
sion transitoire du PGAM chez les deux patients. 
Discussion. — La dépression transitoire du PGAM après contraction volontaire maximale soutenue 
peut représenter la corrélation électrophysiologique de la faiblesse observée cliniquement chez 
les patients. Dans la MC, la faible conductance du chlore pourrait induire des potentiels d’action 
auto-entretenus après contraction volontaire soutenue, déterminant une dépolarisation mem- 
branaire progressive et une perte d’excitabilité des ﬁbres musculaires, résultant alors en une 
parésie transitoire. La mexilétine pourrait empêcher le bloc de conduction d’apparaître en rai- 
son d’une dépolarisation membranaire excessive, réduisant ainsi la dépression transitoire du 
PGAM après contraction soutenue. 
 
 
 
Introduction 
Myotonia congenita (MC) is an inherited disorder charac- 
terized by delayed muscle relaxation and stiffness after 
voluntary activation. It is caused by mutations of CLCN1, 
which encodes the CLC-1 chloride channel of skeletal muscle 
ﬁbers. Both autosomal dominant (Thomsen’s myotonia) and 
autosomal recessive (Becker’s myotonia) forms are known 
[17]. 
The major clinical manifestation of MC is muscle 
stiffness (myotonia) resulting from abnormal membrane 
over-excitation. With repeated movements, the intensity of 
myotonia diminishes over seconds to minutes and may even 
become asymptomatic, a phenomenon called ‘‘warm-up’’. 
The chloride conductance ensures the electrical stability of 
the human muscle membrane and is crucial for counter- 
ing the depolarizing effect of K+ accumulation in T-tubules 
during the action potential. In MC subjects, the tubular 
potassium accumulation resulting from the initially driven 
activity and the low chloride conductance of myotonic mus- 
cle ﬁbres appear to be responsible for the initiation of the 
myotonic discharge [32]. 
Additional common symptoms of MC include pain, weak- 
ness and fatigue [36—38]. In particular, MC patients complain 
 
of transient weakness that appears when the muscles are 
activated after a period of rest; moreover, in some cases 
the force in relation to muscle volume is constantly reduced 
[4,8,22,24,35]. However, transient weakness is only rarely 
reported by patients, who are usually unable to distinguish 
the stiffness secondary to myotonia from fatigue and weak- 
ness following muscle activity. 
Brown [4] ﬁrst observed that a decremental evoked 
compound muscle action potential (CMAP) was notice-  
able when myotonic patients attempted sustained activity 
after rest. The fade of the evoked response was corre- 
lated with the timing of a previous conditioning stimulus 
train or voluntary contraction [4]. At present, the anal- 
ysis of CMAP size variations in response to short or long 
exercise tests has become useful in differentiating mus- 
cle channelopathies and improving knowledge about their 
pathogenesis [10,17,27,31]. 
In the present paper, CMAP changes were recorded before 
and after 1 min of maximal voluntary contraction (MVC) in 
two subjects with MC, one with Thomsen’s myotonia and 
another with Becker’s myotonia. The results were compared 
with those of 20 healthy subjects. In both patients, the 
study was repeated after introduction of mexiletine therapy. 
Although the effectiveness of mexiletine on both stiffness 
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and weakness in MC has been demonstrated [29], little is 
known on the mechanism underlying the effect of mexiletine 
in reducing weakness. 
 
Methods 
 
Patient 1 (Thomsen’s myotonia) 
 
A 40-year-old man presented with a history of stiffness 
secondary to myotonia from early childhood. The stiffness 
improved with activity (‘warm-up’ phenomenon) and got 
worse with cold temperatures. To assess facial myotonia, the 
patient was asked to squeeze his eyes and his lips closed for 
ﬁve seconds then rapidly open them. To assess limb function, 
myotonia was considered present if there was inability to 
release hand grip and if there was the likelihood of tripping 
and falling when walking. Myotonia was present in all four 
limbs and facial muscles, hampering the patient in daily life 
(Video 1). In addition, the patient described weakness after 
prolonged exercise. Physical examination revealed general- 
ized muscle hypertrophy, most prominent in calves, without 
apparent loss of muscle strength. However, the patient 
perceived a drop of power during sustained voluntary activ- 
ity after rest. This experience was clearly different from 
the myotonic stiffness and could be detected by clinical 
examination in both upper and lower extremities. The tran- 
sient weakness was evaluated with the Medical Research 
Council (MRC) scale for muscle strength: shortly after the 
beginning of the muscle contraction there was a decrease 
of the MRC score (from 5 to 3 or 4) in distal and proximal 
muscles. 
A needle electromyogram (EMG) of both proximal and 
distal muscles (rectus femoris, tibialis anterior, biceps 
brachii, extensor carpi radialis, ﬁrst dorsal interosseus mus- 
cles) demonstrated profuse myotonic discharges. Motor unit 
potentials were of normal morphology. Nerve conduction 
study of the upper and lower limbs revealed a mild reduc- 
tion of sensory action potential amplitude of the sural nerves 
(3 and 4 µ,V), indicating a length-dependent mild sensory 
axonal polyneuropathy, only affecting the lower limbs. The 
CLCN1 gene was screened. Sequence analysis evidenced the 
heterozygous G/T change at the aminoacidic position 859, 
leading to the novel p.Gly859Val variant. All the 180 Italian 
control chromosomes screened were negative for the muta- 
tion. The possible pathogenicity was evaluated by the online 
analysis tools MUTPRED (http://mutpred.mutdb.org) and 
SIFT (http://sift.jcvi.org), and both indicated p.Gly859Val 
as damaging. Furthermore, Gly859 is located in CBS2, a 
domain essential in chloride channel functionality. Unfortu- 
nately, DNA samples of the other family members were not 
available to investigate the hereditary pattern, and to draw 
a pedigree. Mexiletine was started at a daily dose of 400 mg 
(200 mg bid) and was then incremented to 600 mg/day 
(200 mg tid) with a dramatic reduction of myotonia, ‘‘warm- 
up’’ phenomenon, and clinical improvement of muscle 
strength during sustained activity in the four limbs (Video 2). 
 
Patient 2 (Becker’s myotonia) 
 
A 38-year-old woman complained from childhood of stiff- 
ness that improved with activity (‘‘warm-up’’ phenomenon) 
and worsened with cold. In addition, she described weak- 
ness after prolonged exercise. The clinical examination was 
performed in the same manner as described above for 
patient 1. Mild myotonic phenomenon was evident only in 
the hands. Physical examination revealed muscle hyper- 
trophy, most prominent in pelvic girdle and quadriceps 
muscles without hypostenia. The transient weakness was 
perceived by the patient as an unexpected lapse of power 
during sustained activity, mostly in the distal muscles. An 
EMG showed the presence of myotonic discharges mainly 
involving the distal muscles of the upper and lower limbs. 
Motor unit potentials were of normal morphology. The nerve 
conduction study was normal. Analysis of CLCN1 revealed 
the known mutation p.Phe167Leu (exon 4) and the novel 
p.Ser289Arg (exon 8) substitution in compound heterozy- 
gous state. Mexiletine 400 mg/day (200 mg bid) was started 
leading to marked improvement of the symptomatology. In 
particular, the myotonic phenomenon almost disappeared 
with improvement of muscle strength during sustained activ- 
ity in the four limbs. 
 
 
Electrophysiology 
 
Both the electrophysiological and clinical tests were per- 
formed before patients were put on mexiletine, and three 
months after initiation of this treatment. In both patients, 
examinations were carried out at the same time of the morn- 
ing. The post mexiletine tests were performed about three 
hours after mexiletine intake. 
To carry out repetitive nerve stimulation studies (RNS), 
ulnar nerve was stimulated at the wrist. The peak-to- 
baseline amplitude and the negative peak area of the motor 
response potentials from abductor digiti minimi (ADM) mus- 
cle were measured, and the percentage decrement was 
calculated between the 1st and 10th responses. Any decre- 
mental response of 10% or more was considered abnormal. 
RNS was performed at 3 Hz, 5 Hz, and 10 Hz. 
The CMAPs were evoked in ADM by electrical stimuli 
applied to the ulnar nerve at the wrist. We examined the 
changes in size of the maximum CMAP before and after MVC 
of ADM for 1 minute. During the electrophysiological test, 
the subjects were lying supine on a bed, with their right 
arm placed parallel to the body, in a neutral position. Spe- 
cial care was taken to prevent any change of position of the 
wrist and ﬁnger joint during ADM contraction and in sub- 
sequent minutes. The stimuli were delivered before MVC, 
immediately after MVC, and at 1-3-5-7 and 10 minutes post- 
MVC. 
The intensity of stimulation was ﬁxed at the level 
required to obtain a maximum CMAP before contraction, and 
then kept constant over the entire study period. Data were 
compared with those obtained in 20 control subjects (ten 
females and ten males; age range, 25—55 years). The con- 
trols were healthy volunteers selected from the medical, 
paramedical and administrative staff of our department. All 
CMAPs values were normalized to their maximum (expressed 
in percentage). 
The ethics committee of University of Siena, Italy, 
approved the study and all patients gave written informed 
consent. 
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Figure 1  Amplitude of the compound muscle action potential (CMAP) recorded from the abductor digiti minimi muscle in response 
to supramaximal ulnar nerve stimulation at the wrist, before and up to 10 minutes after a 1 min exercise of maximum voluntary 
contraction (time ‘‘0’’ being the value measured before contraction; each data being the average of 4—5 CMAPs). Label A refers to 
patient 1 (Thomsen’s myotonia); label B refers to patient 2 (Becker’s myotonia). 
 
Results 
 
Repetitive nerve stimulation at 3 and 5 Hz was unremarkable 
in both subjects, whereas at 10 Hz a signiﬁcant CMAP ampli- 
tude drop was evident in Patient 1 (11%) and Patient 2 (16%). 
In both patients, the decrement became non-signiﬁcant 
after the introduction of mexiletine therapy. 
Fig. 1 shows the decrease in CMAP amplitude and the 
recovery time after MVC with respect to the test CMAP 
amplitude before MVC in MC patients, whereas no change 
was observed in controls. In Patient 1, CMAP amplitude 
reduction peaked in the ﬁrst 10 s after the end of the MVC 
(61% reduction, from 8.8 mV to 3.4 mV); it took 10 minutes 
for CMAP amplitude to return to control value. In patient 
2, CMAP amplitude reduction was less (23%, from 9.1 mV to 
7 mV) and it took 3 minutes to return to control value. 
When the measurements were performed under mexile- 
tine therapy, the maximal CMAP depression after MVC was 
reduced from 61 to 6%, with only 3 minutes to return to con- 
trol value in patient 1, whereas CMAP depression after MVC 
was no longer observable in patient 2. 
 
Discussion 
 
Some MC patients show CMAP amplitude decrement to 
repetitive nerve stimulation, which correlates with the pres- 
ence of transient weakness rather than with the severity of 
myotonia, according to concomitant recordings of CMAP and 
muscle strength under isometric conditions performed in 
autosomal recessive MC [2,4,14,15,23]. In the present study, 
we found a transient reduction in maximal CMAP amplitude 
after 1 min of MVC in two MC patients, whereas no change 
was observed in normal controls. This suggests that virtually 
all ADM motor axons could be still activated after sustained 
contraction in healthy subjects, in line with previous studies 
[3,25,26]. 
Our ﬁndings in Patient 2 are similar to those reported by 
McKay et al. [18] in one case of Becker’s myotonia. Since a 
marked decrement is generally believed to be a hallmark of 
recessive MC, it was somewhat surprising that the patient 
with dominant MC had more decrement than the patient 
with recessive MC. However, both dominant and recessive 
MC mutations share similar pathophysiology, affecting the 
muscle-speciﬁc chloride channel. In addition, previous stud- 
ies have shown that large decrements in CMAP amplitude 
occasionally occurred after contraction in dominant MC, 
with the magnitude of decrement possibly related to muta- 
tion type [7,8] and differences in allelic expression of the 
CLCN1 gene [9]. On the other hand, no data have previously 
been reported regarding CMAP recordings after 1 minute of 
MVC in dominant MC. In this respect, we emphasize the 
novelty of the results obtained in Patient 1 with dominant 
MC. 
The putative factors responsible for activity-induced 
CMAP depression could be located anywhere from the motor 
neuron to the muscle ﬁber. However, we have to consider 
that the Cl− conductance contributes to 85% of the res- 
ting membrane potential in muscle ﬁbers [5], but to only 
10% of the resting membrane potential in motor axons [30]. 
Indeed, the role played by Cl− channels in the human motor 
axons remains debated and moreover the parameters of 
motor axonal excitability were found to be normal in MC  
in a previous study [18]. The most probable explanation   
is that the sustained MVC provokes extreme muscle depo- 
larization due to Na+ inﬂux, thus determining an increased 
Na+ channel inactivation leading to muscle hypoexcitability. 
Indeed, it is documented that natural muscle contraction 
activity may be associated with elevation of extracellu-   
lar K+ concentrations, which in turn could depress muscle 
responses. The inﬂuence of elevated extracellular K+ con- 
centrations and slow-inactivation of Na+ channels induced 
by excessive depolarization may result in a decrease of sar- 
colemmal excitability and the reduction in the number of 
excitable muscle ﬁbers explains CMAP amplitude decrease 
[19,20,28]. On the other hand, the reduced amount of 
CLC-1 chloride channels in muscle ﬁber membrane of MC 
patients diminishes the hyperpolarizing Cl− currents so that 
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K+ accumulation in the T-tubular lumen depolarizes the sur- 
face membrane sufﬁciently to initiate self-sustaining action 
potentials, causing a prolonged (myotonic) contraction [1]. 
Further cumulative and excessive muscle membrane depo- 
larization, such as could occur after prolonged MVC, may 
trigger transient hypoexcitability related to a depolarization 
block, as discussed above. Our ﬁndings of transient CMAP 
depression and delayed recovery of excitability following 
sustained MVC may represent the electrophysiological corre- 
late of the weakness clinically experienced by MC patients. 
After the introduction of mexiletine therapy, the CMAP 
depression following MVC was markedly reduced in the 
patient with Thomsen’s myotonia and disappeared in the 
patient with Becker’s myotonia. Both patients also showed 
no further CMAP amplitude decrement following high- 
frequency RNS under mexiletine. In MC patients, mexiletine 
is thought to decrease repetitive motor unit discharges by 
blocking Na+ channels, since it does not seem to inter- 
act with Cl− channels [11,33]. How such a mechanism may 
explain the positive effect of mexiletine on transient CMAP 
depression following sustained contraction remains to be 
clariﬁed. In fact, given the negative effects of mexiletine 
on motor axon excitability properties in humans [13], one 
would expect an opposite effect compared to that observed 
in the present study and also to that previously shown by 
McKay et al. [18]. 
It is well known that Na+ channel blockers improve 
myotonic stiffness, but also weakness and tiredness [21,24], 
which could explain the overall clinical amelioration of 
myotonic patients reported in a recent clinical trial with 
mexiletine [29]. Mexiletine produces an activity-dependent 
block of voltage-gated Na+ channels (the higher is the 
frequency of action potential discharges, the greater is  
the block) at the origin of its speciﬁc effect on disease- 
related hyperexcitability, such as in the myotonic muscle. 
The correlation between myotonic stiffness and weakness 
in MC is not surprising from a pathophysiological perspec- 
tive [8]. In fact, the block of the myotonic discharge may 
prevent further activity-dependent block due to excessive 
membrane depolarization, thus reducing CMAP depression 
following sustained voluntary contraction. Thus, the most 
noticeable change in post-MVC CMAP depression after ther- 
apy was observed in Patient 1 who had the most severe 
myotonic phenomenon and showed the greatest clinical 
response. 
In Video 2, the reduction of the ‘‘warm-up’’ phenomenon 
was evident after mexiletine therapy. The ‘‘warm-up’’ 
phenomenon is an established clinical feature  in  chlo- 
ride channelopathies, though it has also been shown to 
occur in other myotonic syndromes [6,16,34]. The mecha- 
nism remains unknown. Proposed mechanisms for warm-up 
include Na/K-ATPase up-regulation, decreasing intracellular 
pH, Nav1.4 slow-inactivation or K+ shift into the T-tubules 
[6,16]. On the basis of the mechanism of action of the mex- 
iletine (see above) and its proven effectiveness in reducing 
the ‘‘warm-up’’ phenomenon in different channelopaties 
[29,34], it is plausible that this drug produces lower neuronal 
ﬁring rate that in turn will lead to lesser activity-dependent 
axonal hyperpolarization [12]. These changes could con- 
ceivably decrease ﬁber excitability, thus decreasing the 
likelihood of myotonic discharges and consequently the 
‘‘warm-up’’ phenomenon. 
Conclusion 
 
Our study further conﬁrms that in both recessive and domi- 
nant MC, a proportion of muscle ﬁbers cannot maintain their 
response to nerve stimulation after sustained MVC. This phe- 
nomenon likely represents the physiological counterpart of 
the weakness clinically experienced by the patients. The 
remarkable recovery of neuromuscular excitability following 
the introduction of mexiletine suggests a common mech- 
anism underlying myotonic stiffness and weakness in MC. 
Our results are based on only two cases hence need to be 
conﬁrmed in a larger sample of patients. 
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